Ikkou Hirata
Overview
Explore the profile of Ikkou Hirata including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
8
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Okazaki R, Hirata I, Ikegami H, Rokutanda R, Funakoshi R
Obstet Med
. 2024 Nov;
:1753495X241297559.
PMID: 39605871
Although tumor necrosis factor inhibitors are recommended for preventing flare-ups in pregnant women with ulcerative colitis (UC), studies on golimumab use during pregnancy are scant. Herein, we present a 39-year-old...
2.
Ishihara T, Hirata I, Konaka M, Hamaguchi M, Funakoshi R
Yakugaku Zasshi
. 2024 Oct;
144(10):951-956.
PMID: 39358251
Budesonide Rectal Foam (BF) was introduced in 2017 and changed in November 2022 upon request, addressing the challenges encountered with liquid rectal formulations indicated for ulcerative colitis (UC). This formulation...
3.
Hirata I, Funakoshi R
Yakugaku Zasshi
. 2023 Nov;
143(11):941-949.
PMID: 37914341
Inflammatory bowel disease (IBD) is an autoimmune disease that inflames the intestinal tract and reduces patient quality of life. In recent years, prescriptions of biologics and Janus kinase inhibitors have...
4.
Hirata I, Hanaoka S, Rokutanda R, Funakoshi R, Hayashi H
J Pharm Pharm Sci
. 2023 Mar;
26:11135.
PMID: 36942300
To investigate the value-to-value relationships, relationship between values and patient background, continuation rate of treatment after shared decision-making (SDM), and disease status in order to clarify the values involved in...
5.
Funaki A, Hirata I, Matsui H, Isezaki T, Funakoshi R
Biol Pharm Bull
. 2023 Jan;
46(1):128-132.
PMID: 36596521
Biosimilars (BS) are promoted worldwide because of the high cost of biologics. However, patients are apprehensive about switching to BS. For some diseases, several factors, which may be disease-dependent, influence...
6.
Hirata I, Iwamoto M, Matsui H, Yoshinuma H, Funakoshi R
J Pharm Pharm Sci
. 2020 Jun;
23:220-230.
PMID: 32569560
Purpose: To examine the impact of adding droperidol to fentanyl-based intravenous patient- controlled analgesia (IVPCA) on the discontinuation of IVPCA use due to postoperative nausea and vomiting (PONV). Methods: Patients...